SKYE: Skye Bioscience, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 56.37
Enterprise Value ($M) -12.97
Book Value ($M) 68.15
Book Value / Share 2.20
Price / Book 0.81
NCAV ($M) 66.22
NCAV / Share 2.14
Price / NCAV 0.84

Profitability (mra)
Return on Invested Capital (ROIC) -0.39
Return on Assets (ROA) -0.28
Return on Equity (ROE) -0.34

Liquidity (mrq)
Quick Ratio 16.32
Current Ratio 16.32

Balance Sheet (mrq) ($M)
Current Assets 70.83
Assets 72.76
Liabilities 4.61
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -30.19
Net Income -26.57
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -25.24
Cash from Investing -0.25
Cash from Financing 83.56

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
04-10 13G/A Sphera Funds Management Ltd. 4.77 13.43
12-19 13D/A 5AM Partners VII, LLC 36.40 -1.74
11-14 13G/A Janus Henderson Group Plc 0.00 -100.00
11-14 13G/A Altium Capital Management LP 4.30 1.05

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-20 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-25 132,928 399,013 33.31
2025-04-24 83,966 296,766 28.29
2025-04-23 85,358 379,062 22.52
2025-04-22 92,786 438,084 21.18

(click for more detail)

Similar Companies
SCYX – SCYNEXIS, Inc. SGMT – Sagimet Biosciences Inc.
SIGA – SIGA Technologies, Inc. SMMT – Summit Therapeutics Inc.
SPRY – ARS Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io